Project Details
Description
The first aim, Aim 1.2-1.4 focuses on the effector changes in cDC2s that induce Tfh13s.
Dr. Martin has a drug that in a DC specific manner, reverses Tfh13 polarization by altering cDC2 metabolism. In this aim, they will utilize this drug as a tool to understand amount of antigen presentation, the specific co-stimulatory molecules, cytokines, and transcriptional changes that cDC2s illicit to specifically polarize Tfh13s. Dr. Eisenbarth will provide expertise in Tfh13s to help guide them in interpretation of the data, careful examination of the RNAseq after initial analysis, help with troubleshooting.
| Status | Active |
|---|---|
| Effective start/end date | 12/25/22 → 11/30/27 |
Funding
- Virginia Commonwealth University (FP00017337_SA001 AMD 1 // 5R01HL162991-2)
- National Heart, Lung, and Blood Institute (FP00017337_SA001 AMD 1 // 5R01HL162991-2)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.